Related Experiment Video

Updated: Aug 21, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Managing dyslipidemia in chronic kidney disease

Daniel E Weiner1, Mark J Sarnak

  • 1Division of Nephrology, Tufts-New England Medical Center, Boston, Massachusetts, USA.

Journal of General Internal Medicine
|October 16, 2004
PubMed

Insights

Patients with chronic kidney disease (CKD) face higher cardiovascular disease (CVD) risks. Reviewing dyslipidemia treatment in CKD, current guidelines suggest aggressive lipid management despite limited trial data, with ongoing studies to clarify optimal therapies.

Area of Science:

  • Nephrology
  • Cardiology
  • Clinical Pharmacology

Background:

  • Patients with chronic kidney disease (CKD) exhibit a significantly elevated risk of cardiovascular disease (CVD) compared to the general population.
  • Dyslipidemia is a prevalent and modifiable risk factor for CVD in individuals with CKD.
  • The complex lipid profiles in CKD patients, including 'reverse epidemiology' where low cholesterol correlates with higher mortality, necessitate careful consideration of treatment strategies.

Purpose of the Study:

  • To review existing observational and clinical trial data on dyslipidemia and its management in patients with chronic kidney disease (CKD).
  • To evaluate the safety and efficacy of lipid-lowering therapies in the context of CKD and associated cardiovascular risks.
  • To inform clinical practice and guideline development regarding dyslipidemia treatment in CKD patients.

Main Methods:

  • Comprehensive review of observational studies investigating lipid profiles and mortality in CKD patients.
  • Analysis of clinical trial data assessing the impact of lipid-lowering therapies on cardiovascular outcomes in CKD.
  • Evaluation of current clinical guidelines and recommendations for dyslipidemia management in CKD.

Main Results:

  • Observational data suggest a 'reverse epidemiology' phenomenon in CKD, linking lower total cholesterol to increased mortality.
  • While trial data are limited, many lipid-lowering medications are considered safe and effective for CKD patients.
  • Emerging evidence indicates potential benefits of statin therapy, including reduced inflammation and slowed GFR decline in early CKD stages.

Conclusions:

  • Current guidelines recommend aggressive dyslipidemia therapy for CKD patients due to high CVD rates and medication safety.
  • A significant paucity of robust trial data specific to CKD populations exists.
  • Three ongoing randomized controlled trials are expected to provide definitive evidence on statin therapy's effect on CVD outcomes in CKD.
Abstract

More Related Videos

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

Related Concept Videos

Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
Chronic Kidney Disease IV: Nursing Management01:18

Chronic Kidney Disease IV: Nursing Management

Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care​.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of fluid...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...